A Phase 4 interventional study of tocilizumab and methotrexate in Rheumatoid Arthritis, sponsored by Genentech, Inc.. Completed at 47 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2012-12-07.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 58th largest by enrollment, is one of 14 that started in 2010, is one of 32 in phase 4, and was the 35th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Marie Hudson, MD · Sites in Canada
Ages 18+
Reade Rheumatology Research Institute · Sites in Netherlands
Ages 18+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 65 · Phase 4 32
First in 2001; this study’s year is marked. 14 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 91 is close to the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 97 across the 110 interventional studies. Of the 98 that completed or were terminated, 66 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 110 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 86th largest by enrollment of the 141 interventional ones that give a count, is one of 26 that started in 2010, is one of 28 in phase 4, and was the 83rd registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This randomized, parallel-group, open-label study will evaluate the effect of Actemra (tocilizumab) on vaccination in patients with active rheumatoid arthritis who have an inadequate response to methotrexate and who have had an inadequate clinical response or were intolerant to treatment with one or more anti-tumor necrosis factor (anti-TNF) therapies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants continued to receive their standard dose of methotrexate up to Week 8. From Week 8 participants also received 8 mg/kg tocilizumab intravenously every 4 weeks until Week 20. At Week 3 participants received both pneumococcal and tetanus toxoid vaccinations.
Biological: tocilizumab · Drug: methotrexate · Biological: 23-Valent Pneumococcal Polysaccharide Vaccine · Biological: Tetanus Toxoid Adsorbed Vaccine
Participants received 8 mg/kg tocilizumab intravenously at Baseline (Day 1) and every 4 weeks up to Week 20, in addition to their standard dose of methotrexate. At Week 3 participants received both pneumococcal and tetanus toxoid vaccinations.
Biological: tocilizumab · Drug: methotrexate · Biological: 23-Valent Pneumococcal Polysaccharide Vaccine · Biological: Tetanus Toxoid Adsorbed Vaccine
Intravenous repeating dose
Also known as: RoActemra, Actemra
A stable dose of between 7.5 and 25 mg/week, oral or parenteral.
Intramuscular or subcutaneous injection
Also known as: Pneumovax
Intramuscular injection
Percentage of Participants Who Responded to ≥ 6 of 12 Anti-pneumococcal Antibody Serotypes
Serum levels of antibody to pneumococcal vaccine were drawn 5 weeks after vaccination with 23-valent pneumococcal polysaccharide vaccine to assess humoral immune response. A positive response to the pneumococcal vaccine was defined as a 2-fold increase in serum antibody titers from Baseline or an increase of \> 1 mg/L from Baseline levels. The 12 serotypes evaluated were pneumococcal serotypes 1, 3, 4, 6B, 8, 9N, 12F, 14, 19F, 23F, 7F, and 18C.
Time frame: Baseline (Week 3) and Week 8 (5 weeks post-vaccination)
Percentage of Participants Who Responded to Combinations of 12 Anti-Pneumococcal Antibody Serotypes
Serum levels of antibody to pneumococcal vaccine were drawn 5 weeks after vaccination with 23-valent pneumococcal polysaccharide vaccine to assess humoral immune response. A positive response to the pneumococcal vaccine was defined as a 2-fold increase in serum antibody titers from Baseline or an increase of \> 1 mg/L from Baseline levels. The 12 serotypes evaluated were pneumococcal serotypes 1, 3, 4, 6B, 8, 9N, 12F, 14, 19F, 23F, 7F, and 18C.
Time frame: Baseline (Week 3) and Week 8 (5 weeks post-vaccination)
Percentage of Participants With a Positive Response to Tetanus Toxoid Vaccination
A positive response to the tetanus toxoid vaccination was defined as antibody levels ≥ 0.2 IU/mL for participants with Baseline tetanus antibody levels \< 0.1 IU/mL, or a 4-fold increase in antibody levels compared with Baseline for participants with Baseline tetanus antibody levels ≥ 0.1 IU/mL.
Time frame: Baseline (Week 3) and Week 8 (5 weeks post-vaccination)
Change From Baseline in Levels of Anti-pneumococcal Antibody 5 Weeks After Vaccination
Levels of anti-pneumococcal antibodies were measured by a central laboratory from serum samples taken prior to vaccination (Week 3) and 5 weeks post vaccination (Week 8).
Time frame: Baseline (Week 3) and Week 8 (5 weeks post-vaccination)
Change From Baseline in Levels of Anti-tetanus Antibody 5 Weeks After Vaccination
Levels of anti-tetanus antibodies were measured by a central laboratory from serum samples taken prior to vaccination (Week 3) and 5 weeks post vaccination (Week 8).
Time frame: Baseline (Week 3) and Week 8 (5 weeks post-vaccination)
Percentage of Participants Who Responded to Each of the 12 Anti-Pneumococcal Antibody Serotypes
Serum levels of antibody to pneumococcal vaccine were drawn 5 weeks after vaccination with 23-valent pneumococcal polysaccharide vaccine to assess humoral immune response. A positive response to the pneumococcal vaccine was defined as a 2-fold increase in serum antibody titers from Baseline or an increase of \> 1 mg/L from Baseline levels. The 12 serotypes evaluated were pneumococcal serotypes 1, 3, 4, 6B, 7F, 8, 9N, 12F, 14, 18C, 19F and 23F.
Time frame: Baseline (Week 3) and Week 8 (5 weeks post-vaccination)
Number of Participants With Adverse Events Through Week 8
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A Serious Adverse Event (SAE) is any AE that is fatal or is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is medically significant or requires intervention to prevent one or other of the outcomes listed above.
Time frame: 8 weeks
| Milestone | Methotrexate | Tocilizumab + Methotrexate |
|---|---|---|
| Started | 31 | 60 |
| Per protocol population | 27 | 54 |
| Completed | 25 | 49 |
| Not completed | 6 | 11 |
| Withdrew: Adverse event | 0 | 5 |
| Withdrew: Insufficient therapeutic response | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Refused treatment | 6 | 4 |
Serum levels of antibody to pneumococcal vaccine were drawn 5 weeks after vaccination with 23-valent pneumococcal polysaccharide vaccine to assess humoral immune response. A positive response to the pneumococcal vaccine was defined as a 2-fold increase in serum antibody titers from Baseline or an increase of \> 1 mg/L from Baseline levels. The 12 serotypes evaluated were pneumococcal serotypes 1, 3, 4, 6B, 8, 9N, 12F, 14, 19F, 23F, 7F, and 18C.
| percentage of participants | Methotrexate | Tocilizumab + Methotrexate |
|---|---|---|
| Percentage of Participants Who Responded to ≥ 6 of 12 Anti-pneumococcal Antibody Serotypes | 70.8 (52.6 to 89.0) | 60.0 (46.4 to 73.6) |
Serum levels of antibody to pneumococcal vaccine were drawn 5 weeks after vaccination with 23-valent pneumococcal polysaccharide vaccine to assess humoral immune response. A positive response to the pneumococcal vaccine was defined as a 2-fold increase in serum antibody titers from Baseline or an increase of \> 1 mg/L from Baseline levels. The 12 serotypes evaluated were pneumococcal serotypes 1, 3, 4, 6B, 8, 9N, 12F, 14, 19F, 23F, 7F, and 18C.
| percentage of participants | Methotrexate | Tocilizumab + Methotrexate |
|---|---|---|
| Responded to ≥1 out of 12 serotypes | 87.5 (74.3 to 100.0) | 90.0 (81.7 to 98.3) |
| Responded to ≥2 out of 12 serotypes | 87.5 (74.3 to 100.0) | 86.0 (76.4 to 95.6) |
| Responded to ≥3 out of 12 serotypes | 83.3 (68.4 to 98.2) | 80.0 (68.9 to 91.1) |
| Responded to ≥4 out of 12 serotypes | 83.3 (68.4 to 98.2) | 74.0 (61.8 to 86.2) |
| Responded to ≥5 out of 12 serotypes | 83.3 (68.4 to 98.2) | 66.0 (52.9 to 79.1) |
| Responded to ≥6 out of 12 serotypes | 70.8 (52.6 to 89.0) | 60.0 (46.4 to 73.6) |
| Responded to ≥7 out of 12 serotypes | 58.3 (38.6 to 78.1) | 54.0 (40.2 to 67.8) |
| Responded to ≥8 out of 12 serotypes | 58.3 (38.6 to 78.1) | 38.0 (24.5 to 51.5) |
| Responded to ≥9 out of 12 serotypes | 45.8 (25.9 to 65.8) | 32.0 (19.1 to 44.9) |
| Responded to ≥10 out of 12 serotypes | 29.2 (11.0 to 47.4) | 20.0 (8.9 to 31.1) |
| Responded to ≥ 11 out of 12 serotypes | 20.8 (4.6 to 37.1) | 12.0 (3.0 to 21.0) |
| Responded to 12 out of 12 serotypes | 8.3 (0.0 to 19.4) | 6.0 (0.0 to 12.6) |
A positive response to the tetanus toxoid vaccination was defined as antibody levels ≥ 0.2 IU/mL for participants with Baseline tetanus antibody levels \< 0.1 IU/mL, or a 4-fold increase in antibody levels compared with Baseline for participants with Baseline tetanus antibody levels ≥ 0.1 IU/mL.
| percentage of participants | Methotrexate | Tocilizumab + Methotrexate |
|---|---|---|
| Percentage of Participants With a Positive Response to Tetanus Toxoid Vaccination | 39.1 (19.2 to 59.1) | 42.0 (28.3 to 55.7) |
Levels of anti-pneumococcal antibodies were measured by a central laboratory from serum samples taken prior to vaccination (Week 3) and 5 weeks post vaccination (Week 8).
| mg/L | Methotrexate | Tocilizumab + Methotrexate |
|---|---|---|
| Baseline | 91.1 ± 122.91 | 73.9 ± 63.50 |
| Week 8 | 307.2 ± 270.25 | 184.2 ± 197.99 |
| Change from Baseline | 216.1 ± 261.85 | 110.2 ± 188.74 |
Levels of anti-tetanus antibodies were measured by a central laboratory from serum samples taken prior to vaccination (Week 3) and 5 weeks post vaccination (Week 8).
| IU/mL | Methotrexate | Tocilizumab + Methotrexate |
|---|---|---|
| Baseline | 2 ± 1.3 | 2 ± 1.9 |
| Week 8 | 9 ± 12.4 | 9 ± 9.2 |
| Change from Baseline | 7 ± 12.3 | 7 ± 9.0 |
Serum levels of antibody to pneumococcal vaccine were drawn 5 weeks after vaccination with 23-valent pneumococcal polysaccharide vaccine to assess humoral immune response. A positive response to the pneumococcal vaccine was defined as a 2-fold increase in serum antibody titers from Baseline or an increase of \> 1 mg/L from Baseline levels. The 12 serotypes evaluated were pneumococcal serotypes 1, 3, 4, 6B, 7F, 8, 9N, 12F, 14, 18C, 19F and 23F.
| percentage of participants | Methotrexate | Tocilizumab + Methotrexate |
|---|---|---|
| Serotype 1 response [N=24, 49] | 79.2 | 65.3 |
| Serotype 3 response [N=24, 49] | 62.5 | 53.1 |
| Serotype 4 response [N=24, 50] | 33.3 | 38.0 |
| Serotype 6B response [N=24, 50] | 58.3 | 46.0 |
| Serotype 7F response [N=24, 49] | 66.7 | 61.2 |
| Serotype 8 response [N=24, 49] | 75.0 | 59.2 |
| Serotype 9N response [N=23, 50] | 73.9 | 56.0 |
| Serotype 12F response [N=23, 49] | 21.7 | 26.5 |
| Serotype 14 response [N=21, 50] | 57.1 | 56.0 |
| Serotype 18C response [N=24, 50] | 79.2 | 64.0 |
| Serotype 19F response [N=24, 50] | 70.8 | 54.0 |
| Serotype 23F response [N=24, 50] | 50.0 | 44.0 |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A Serious Adverse Event (SAE) is any AE that is fatal or is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is medically significant or requires intervention to prevent one or other of the outcomes listed above.
| participants | Methotrexate | Tocilizumab + Methotrexate |
|---|---|---|
| Any adverse event | 3 | 23 |
| Serious adverse event | 1 | 2 |
| Deaths | 0 | 0 |
| Withdrawals due to adverse events | 0 | 1 |
Collected over From Day 1 through Week 28.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Methotrexate | — | 1/31 (3.2%) | 9/31 (29%) |
| Tocilizumab + Methotrexate | — | 3/60 (5%) | 25/60 (41.7%) |
| Event | Methotrexate | Tocilizumab + Methotrexate |
|---|---|---|
| CellulitisInfections and infestations | 1/31 | 1/60 |
| Intraspinal abscessInfections and infestations | 0/31 | 1/60 |
| Staphylococcal sepsisInfections and infestations | 0/31 | 1/60 |
| DehydrationMetabolism and nutrition disorders | 0/31 | 1/60 |
| Hypertensive crisisVascular disorders | 0/31 | 1/60 |
| Event | Methotrexate | Tocilizumab + Methotrexate |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 3/31 | 4/60 |
| SinusitisInfections and infestations | 1/31 | 5/60 |
| NauseaGastrointestinal disorders | 1/31 | 4/60 |
| HeadacheNervous system disorders | 0/31 | 4/60 |
| NasopharyngitisInfections and infestations | 2/31 | 3/60 |
| Urinary tract infectionInfections and infestations | 2/31 | 2/60 |
| BronchitisInfections and infestations | 0/31 | 3/60 |
| AnxietyPsychiatric disorders | 0/31 | 3/60 |
| RashSkin and subcutaneous tissue disorders | 0/31 | 3/60 |
| Age Continuous(years) | Methotrexate | Tocilizumab + Methotrexate | Total |
|---|---|---|---|
| Mean | 51.4 ± 9.47 | 51.1 ± 8.90 | 51.2 ± 9.04 |
| Sex: Female, Male(Participants) | Methotrexate | Tocilizumab + Methotrexate | Total |
|---|---|---|---|
| Female | 22 | 41 | 63 |
| Male | 5 | 13 | 18 |
| Region of Enrollment(participants) | Methotrexate | Tocilizumab + Methotrexate | Total |
|---|---|---|---|
| United States | 27 | 54 | 81 |
The record gives a start of Sep 2010, a primary completion of Dec 2011 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2012, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tocilizumab · Methotrexate